These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15127675)

  • 1. Dopamine agonist switching in Parkinson's disease.
    Stewart D; Morgan E; Burn D; Grosset D; Chaudhuri KR; MacMahon D; Needleman F; Macphee G; Heywood P
    Hosp Med; 2004 Apr; 65(4):215-9. PubMed ID: 15127675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of apomorphine in Parkinson's disease.
    O'Sullivan JD; Lees AJ
    Hosp Med; 1999 Nov; 60(11):816-20. PubMed ID: 10707193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?
    Goetz CG; Blasucci L; Stebbins GT
    Neurology; 1999 Apr; 52(6):1227-9. PubMed ID: 10214748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrosis associated with dopamine agonist therapy in Parkinson's disease.
    Müller T; Fritze J
    Clin Neuropharmacol; 2003; 26(3):109-11. PubMed ID: 12782910
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
    Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
    Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine agonists: their role in the treatment of Parkinson's disease.
    Brooks DJ
    J Neurol Neurosurg Psychiatry; 2000 Jun; 68(6):685-9. PubMed ID: 10811688
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopamine receptor agonists in the therapy of Parkinson's disease.
    Foley P; Gerlach M; Double KL; Riederer P
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1375-446. PubMed ID: 15480844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine receptor agonists and sleep disturbances in Parkinson's disease.
    Chaudhuri KR; Logishetty K
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S101-4. PubMed ID: 20123546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of dopamine agonists in very elderly patients with Parkinson's disease.
    Shulman LM; Minagar A; Rabinstein A; Weiner WJ
    Mov Disord; 2000 Jul; 15(4):664-8. PubMed ID: 10928576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):83-90. PubMed ID: 28745677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
    Mokhles MM; Trifirò G; Dieleman JP; Haag MD; van Soest EM; Verhamme KM; Mazzaglia G; Herings R; Luise Cd; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; Camp Gv; Zanettini R; Sturkenboom MC
    Pharmacol Res; 2012 Mar; 65(3):358-64. PubMed ID: 22123498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing dopamine agonists in Parkinson's disease.
    Bonuccelli U
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S13-9. PubMed ID: 15180133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hiccups in Parkinson's disease: an analysis of cases reported in the European pharmacovigilance database and a review of the literature.
    Lertxundi U; Marquínez AC; Domingo-Echaburu S; Solinís MÁ; Calvo B; Del Pozo-Rodríguez A; García M; Aguirre C; Isla A
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1159-1164. PubMed ID: 28600702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choosing the right dopamine agonist for patients with Parkinson's disease.
    Lebrun-Frenay C; Borg M
    Curr Med Res Opin; 2002; 18(4):209-14. PubMed ID: 12201621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dopamine agonist in the treatment of Parkinson's disease].
    Kuran W
    Neurol Neurochir Pol; 1997; 31(3):545-54. PubMed ID: 9446045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pergolide monotherapy for Parkinson's disease.
    van der Worp B
    J Neurol; 1999 Oct; 246(10):983-4. PubMed ID: 10610397
    [No Abstract]   [Full Text] [Related]  

  • 20. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.